Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials
Identifieur interne : 001614 ( Main/Corpus ); précédent : 001613; suivant : 001615Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials
Auteurs : O. Lindvall ; A. BjörklundSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1989-11.
English descriptors
- KwdEn :
Abstract
Abstract– Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage. Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients. Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model. The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.
Url:
DOI: 10.1111/j.1600-0404.1989.tb01802.x
Links to Exploration step
ISTEX:2154003082A1DB396272D1805C64C2E1AF3F1DF7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title><author><name sortKey="Lindvall, O" sort="Lindvall, O" uniqKey="Lindvall O" first="O." last="Lindvall">O. Lindvall</name><affiliation><mods:affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Lund, Lund, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Bjorklund, A" sort="Bjorklund, A" uniqKey="Bjorklund A" first="A." last="Björklund">A. Björklund</name><affiliation><mods:affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2154003082A1DB396272D1805C64C2E1AF3F1DF7</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1111/j.1600-0404.1989.tb01802.x</idno><idno type="url">https://api.istex.fr/document/2154003082A1DB396272D1805C64C2E1AF3F1DF7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001614</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title><author><name sortKey="Lindvall, O" sort="Lindvall, O" uniqKey="Lindvall O" first="O." last="Lindvall">O. Lindvall</name><affiliation><mods:affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Lund, Lund, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Bjorklund, A" sort="Bjorklund, A" uniqKey="Bjorklund A" first="A." last="Björklund">A. Björklund</name><affiliation><mods:affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11">1989-11</date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="210">210</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">2154003082A1DB396272D1805C64C2E1AF3F1DF7</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01802.x</idno><idno type="ArticleID">ANE197</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine</term><term>fetal tissue</term><term>striatum</term><term>transplantation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract– Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage. Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients. Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model. The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>O. Lindvall</name><affiliations><json:string>Department of Medical Cell Research, University of Lund, Lund, Sweden</json:string><json:string>Department of Neurology, University of Lund, Lund, Sweden</json:string></affiliations></json:item><json:item><name>A. Björklund</name><affiliations><json:string>Department of Medical Cell Research, University of Lund, Lund, Sweden</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>transplantation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>striatum</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fetal tissue</value></json:item></subject><articleId><json:string>ANE197</json:string></articleId><language><json:string>eng</json:string></language><abstract>Abstract– Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage. Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients. Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model. The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.</abstract><qualityIndicators><score>8.5</score><pdfVersion>1.4</pdfVersion><pdfPageSize>486 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1873</abstractCharCount><pdfWordCount>8711</pdfWordCount><pdfCharCount>54811</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>279</abstractWordCount></qualityIndicators><title>Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title><genre><json:string>article</json:string></genre><host><volume>80</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>14</total><last>210</last><first>197</first></pages><issn><json:string>0001-6314</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1111/j.1600-0404.1989.tb01802.x</json:string></doi><id>2154003082A1DB396272D1805C64C2E1AF3F1DF7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2154003082A1DB396272D1805C64C2E1AF3F1DF7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2154003082A1DB396272D1805C64C2E1AF3F1DF7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2154003082A1DB396272D1805C64C2E1AF3F1DF7/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title><author><persName><forename type="first">O.</forename><surname>Lindvall</surname></persName><affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</affiliation><affiliation>Department of Neurology, University of Lund, Lund, Sweden</affiliation></author><author><persName><forename type="first">A.</forename><surname>Björklund</surname></persName><note type="correspondence"><p>Correspondence: Address: Anders Björklund, M.D. Dept of Medical Cell Research Biskopsgatan 5 S‐223 62 Lund Sweden</p></note><affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11"></date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="210">210</biblScope></imprint></monogr><idno type="istex">2154003082A1DB396272D1805C64C2E1AF3F1DF7</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01802.x</idno><idno type="ArticleID">ANE197</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract– Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage. Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients. Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model. The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>transplantation</term></item><item><term>Parkinson's disease</term></item><item><term>dopamine</term></item><item><term>striatum</term></item><item><term>fetal tissue</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2154003082A1DB396272D1805C64C2E1AF3F1DF7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="11000"><doi origin="wiley">10.1111/ane.1989.80.issue-s126</doi><numberingGroup><numbering type="journalVolume" number="80">80</numbering><numbering type="supplement">s126</numbering></numberingGroup><coverDate startDate="1989-11">November 1989</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0019700" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1989.tb01802.x</doi><idGroup><id type="unit" value="ANE197"></id></idGroup><countGroup><count type="pageTotal" number="14"></count></countGroup><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="197">197</numbering><numbering type="pageLast" number="210">210</numbering></numberingGroup><correspondenceTo>Address: Anders Björklund, M.D. Dept of Medical Cell Research Biskopsgatan 5 S‐223 62 Lund Sweden</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE197.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="95"></count><count type="linksCrossRef" number="4"></count></countGroup><titleGroup><title type="main">Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1 #a2"><personName><givenNames>O.</givenNames><familyName>Lindvall</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1" corresponding="yes"><personName><givenNames>A.</givenNames><familyName>Björklund</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="SE"><unparsedAffiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="SE"><unparsedAffiliation>Department of Neurology, University of Lund, Lund, Sweden</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">transplantation</keyword><keyword xml:id="k2">Parkinson's disease</keyword><keyword xml:id="k3">dopamine</keyword><keyword xml:id="k4">striatum</keyword><keyword xml:id="k5">fetal tissue</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract– </b> Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage.</p><p>Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients.</p><p>Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model.</p><p>The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials</title></titleInfo><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Lindvall</namePart><affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</affiliation><affiliation>Department of Neurology, University of Lund, Lund, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Björklund</namePart><affiliation>Department of Medical Cell Research, University of Lund, Lund, Sweden</affiliation><description>Correspondence: Address: Anders Björklund, M.D. Dept of Medical Cell Research Biskopsgatan 5 S‐223 62 Lund Sweden</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1989-11</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">95</extent></physicalDescription><abstract lang="en">Abstract– Neural grafting has over the last decade emerged as a possible tool for the substitution of damaged neurons in the central nervous system and for the promotion of symptomatic recovery after brain damage. Transplantation studies in the 6‐hydroxydopamine lesion rat model of Parkinson's disease were initiated in the late seventies. The first studies were based on the neuronal replacement paradigm, using developing dopamine brain cells obtained from the substantia nigra region of embryonic cadavers. When implanted into the striatum such grafts were found to reinnervate part of the previously denervated striatum and restore dopamine turnover and release to near‐normal levels. In both rats and monkeys the nigral grafts have been shown to normalize some, but not all, Parkinson‐like symptoms in the dopamine deficient recipients. Grafting of adrenal medullary tissue was introduced in the early eighties as an alternative to the use of embryonic cadaver tissue. The adrenal medullary grafts have, however, so far shown poor long‐term survival in both rats and monkeys, and consistent with this no sustained dopamine release have been observed in the brain of long‐term grafted animals. Likewise, no long‐lasting effects of adrenal medullary grafts on spontaneous motor or sensori‐motor behavior have so far been documented in either the rat or the monkey model. The results so far reported from trials using adrenal medullary grafts in patients with Parkinson's disease appear to conform to the available animal experimental data at least in two important respects: significant long‐term graft survival has not been possible to document, and any clear‐cut functional effects consistent with sustained graft‐induced dopamine release have not been demonstrated. Initial results from ongoing trials using grafts of fetal nigral tissue are presented and discussed.</abstract><subject lang="en"><genre>Keywords</genre><topic>transplantation</topic><topic>Parkinson's disease</topic><topic>dopamine</topic><topic>striatum</topic><topic>fetal tissue</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s126</number></detail><extent unit="pages"><start>197</start><end>210</end><total>14</total></extent></part></relatedItem><identifier type="istex">2154003082A1DB396272D1805C64C2E1AF3F1DF7</identifier><identifier type="DOI">10.1111/j.1600-0404.1989.tb01802.x</identifier><identifier type="ArticleID">ANE197</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001614 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001614 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2154003082A1DB396272D1805C64C2E1AF3F1DF7
|texte= Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials
}}
| This area was generated with Dilib version V0.6.23. |  |